๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI ยท Real-Time Price ยท USD
7.06
-0.14 (-1.88%)
Nov 20, 2026, 11:22 AM EST - Market open
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Q3 revenue grew 10%, with mRNA up 28% and discovery up 27% as demand improved. ModTail GMP revenue is expected from H2 2027, while commercial pipeline and operating leverage support longer-term growth and margin expansion.

Matt Stanton
Equity Research Analyst, Jefferies

All right. Great. I think we'll get started. My name's-

Raj Asarpota
CFO, Maravai LifeSciences

James.

Matt Stanton
Equity Research Analyst, Jefferies

Matt Stanton. I'm on the life science tools diagnostics team here at Jefferies. Happy to have Maravai back with us at the conference again this year. I'm going to hand it over to Raj for some opening comments, and then we'll kick it back over here for some Q&A. With that, over to you.

Raj Asarpota
CFO, Maravai LifeSciences

Matt, thank you for having us and hosting us. I'll be making forward-looking statements today, so keeping that in mind. Like Matt said, a quick overview on the company. Maravai LifeSciences is a leading provider of critical technologies and products in the mRNA space that enable the development and manufacturing of life-changing therapeutics, vaccines, and diagnostics, with a particular focus on nucleic acid production and biologics safety testing. We go to market with. Let me step back. We go to market with two marquee brand names or franchises, TriLink and Cygnus, that I'll touch on. The reporting segments that we have, Cygnus and TriLink, each have different growth dynamics. To kind of break that down a little bit, TriLink represents about 65% of our revenues.

Within TriLink, there are three sub-segments, the flagship being mRNA, that consists of discovery, that's research and preclinical, GMP, and commercial revenues that will fold into the company starting in 2028 and 2029. That represents 35% of top line and expected to grow high single digits today. As you move into commercial, those revenues will add to the growth rate, making it a little bit more around like low double digits. CDMO is our contract manufacturing piece, accounting for less than 10% of revenue, growing at low double digits, and then finishing off with specialty chemistry. That's oligo synthesis consumables, just over 20%, representing low single digits. Really, TriLink is pretty diversified, but a lot of emphasis on high growth and commercial upside within mRNA. To round it off, Cygnus is 35% of revenue. This is our bioprocessing tools and analytics business.

Cygnus is the gold standard, and it delivers steady high margins, and we have that in our model at growing at mid-single digits. When you think about mRNA drug development, TriLink as a company, we participate in every stage. Notwithstanding the spies are us, like bad press on NVIDIA, I think it is still a good analogy. Just like NVIDIA doesn't build the AI models, but supplies the compute that every model runs on, similarly, Maravai doesn't develop the drug, but we supply the leading technologies and services that hundreds of mRNA and genetic medicine programs are built on.

As you look at these phases of drug development, from basic research to preclinical, clinical, and commercial, on the basic research side, that is where we seed the market and the start of new programs by supplying research-grade CleanCap, ModTail, oligos, et cetera, which then kind of scale up in preclinical, where we are also selling CleanCap, ModTail, and enzymes. Then once you move into clinical, that is where the GMP volume and price step-up is pretty significant. If you look at our customer base today, we have 50 GMP customers, and each of those customers have two to three programs in the works, so you can get an idea on the shots at goal we have.

As those programs kind of progress through the clinic into commercial, once they get into the commercial space, you are now looking at five different modalities that I will talk about, but they range in terms of value from $5 million for a prophylactic vaccine to over $50 million for other modalities per program per year. So, a little bit on the phase advancement and how that factors into our revenue per program. If you think about preclinical, and then once programs get into the clinic, we probably weight every phase in our long-range plan to include modality risk, because not every program is going to succeed. As you look at this slide, when a program is in the preclinical stage, the estimated chances of reaching the market are pretty small.

But then as you walk through the different phases in the clinic, at phase I, we have a 10% chance. Phase I to II, that goes to 12%. By the time a program is in phase III, there is a 60% chance that it hits the market. So we take all of that into account, and you can see as you move from phase I to phase III and when it gets to market, our share of consumables increases in terms of revenue performance. Then, this is the money page in terms of how we think about modalities that will provide the commercial upside that I spoke of for 2028 and 2029.

These five modalities, the formula here is you look at the number of patients that would receive treatment per year, times the number of doses administered per year, and the mRNA within mRNA per dose to get to a price realization that delivers the expected value per program. For a prophylactic vaccine, the patients per year, that is pretty high, but the doses per year is low, similar to what a COVID vaccine would be. Also the mRNA per dose on the low side. The price realization here, given that it is more batch sizes and large scale, the expected value of that program is pretty low. But then when you advance to personalized medicine and cancer vaccines and mRNA therapeutics, here, the amount of doses increases significantly. Think about a prophylactic vaccine, maybe 35 to 50 micrograms.

You are now with a cancer vaccine stepping up to one milligram that is administered nine, 10 times, so it grows significantly larger. For an mRNA therapeutic, it is even 15 times higher. So when you apply that into the algorithm to think about the price realization and the amount of mRNA per dose, these offer significantly higher value in terms of commercial realization. Again, the takeaway here is $5 million for a vaccine to $50 million per program per year for the other modalities once they get to peak. Then the mix of our pipeline. The current clinical program mix by phase, we have about 40% programs are in phase I, 40% in phases I, II, and then 20% in phase II and phase III. Again, 50 GMP customers in 2026, averaging two to three programs.

Majority of our clinical pipeline is on the higher modalities that I showed versus the prophylactic vaccine example. Then I will just finish off by saying, programs in the clinical today use CleanCap, and then the programs that enter the clinic now will not only incorporate CleanCap and GMP enzymes, but also our new ModTail program, so it has a significant ramp-up in terms of the value for programs that are on the come. With that, I will now if we can get into some Q&A.

Matt Stanton
Equity Research Analyst, Jefferies

All right, perfect. That is very helpful. Appreciate that. Maybe just to kick off, being helpful to get the state of a union across kind of biopharma market. You had a good Q3, raised numbers, talked about, I think, pretty broad-based demand trends you are seeing. Would love to just kind of unpack, are you starting to see some of the funding we have seen the last few quarters translate into spend at the earlier biotechs? Then also just the large pharma side, how are they kind of thinking about mRNA today and kind of the demand across the various customer bases within biopharma?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. Great question. Demand, as we see it, is kind of broad-based and improving quite a bit. In the third quarter, we grew our revenue enterprise by 10%, but mRNA itself grew 28%, and Cygnus had 8% growth. I think on all of those metrics, we significantly have been performing well. If you look at our discovery business in particular, that grew 27% after Q1 growth of 5%, kind of ramping up to 15%, and then eventually 27% in the third quarter after declining 20% in the year before. We think all the COVID destocking is kind of in the rearview mirror right now, and biopharma's advancing programs, and we are seeing that kind of translate into our GMP results quite nicely.

Customers are coming back to us, one, because we have ModTail, but beyond that, if you look at the full breadth of products now on IVT kits, GMP enzymes, NTPs, it's like a full suite of products, and we are completely seeing that happen. I would say the other factor that's driving a lot of the growth in discovery is the whole mRNAbuilder. As customers come to us for these mRNA construct approaches and they can design what they want, we can provide that, and again, that's been a nice growth driver.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. Maybe as we think about just the durability of those demand drivers, right, like you said, mRNA or GMP consumables, very healthy demand. You have a number of new products, ModTail being the big one, but now there's a number that are kind of seeing nice adoption. How do we think about durability, visibility of these as we think about growth into 2027? Then maybe just a finer point on the GMP COVID-related CleanCap, what that number was this year, and then will that be in the guide, or are you going to kind of level set it

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Matt Stanton
Equity Research Analyst, Jefferies

and kind of orient to the base business?

Raj Asarpota
CFO, Maravai LifeSciences

Let me take that one first because it's pretty simple. $14 million and change in the first quarter. We are encouraging everybody to take that out of the guide, and that's how we are thinking about it when we talk about that in February, is keep that outside, and if it happens, it's upside. Until we have line of sight into a commitment, we're not going to put that in our guides. So, you look at the base business, the growth drivers, that's how you should think and model the business, and put COVID aside. That's part one. In terms of durability, I mean, let's take ModTail as an example. We introduced that last year after getting to 70 customers in Q1 that ramped up to 125. Now it's north of 185. So we see that research traction continue.

Once GMP is introduced at the end of this year, we see a lot of traction in the back half of 2027 as it starts to scale up, then that adds an additional dimension to growth on ModTail. Again, I'm going to reflect back on the discovery number, which was, like I said, grew 27%. It certainly indicates to us that we are taking a lot of share right now because the market's not growing that fast. We landed a record 70-plus customers in the third quarter. We had 67-ish customers in Q2, which was also a record. So there's no reason why that momentum shouldn't continue. Having said that, two quarters does not make a trend. As we think about 2027, we want to make sure that it's sustainable, so we'll guide accordingly.

Matt Stanton
Equity Research Analyst, Jefferies

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Matt Stanton
Equity Research Analyst, Jefferies

Maybe just on the Cygnus side, I think we've seen kind of solid mid-single-digit growth there. You guys have kind of outlined potential levers to get that closer to high singles. You have kind of commercial initiatives, you have new product launches, services you're laying in, like-

Raj Asarpota
CFO, Maravai LifeSciences

Right

Matt Stanton
Equity Research Analyst, Jefferies

Talk about some of those coming into Cygnus as we think about potential for that to accelerate a bit into 2027 and beyond with those levers you have-

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. Some of those we've already kind of made moves on. We've onboarded a new leader in China to, again, work with distributors and customers directly and smooth some of that volatility we've seen in recent quarters. We're doing something similar in the U.S. Today, we have a lot of business development that drives revenue, but it's not the same as having a direct commercial presence, so we are looking to do that. On the innovation side, on MockV, we had an additional SV40 kit that was introduced, along with the Protein A Mix-N-Go. I always have trouble with that, but Mix-N-Go kit that is also continuing to add to the innovation. Then beyond that, we talked a little bit about the services business. We invested in an additional mass spec machine last year. It's slightly longer term, but we think that has growth potential as well.

You go from mid-single digits to adding a couple of points of growth through these initiatives.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. Maybe just kind of on that topic, NPIs more broadly, I think a lot of focus is on ModTail and the launch there, rightfully so. But you talked about the enzymes and the mRNAbuilder, Mix-N-Go, new MockV kit, right? As we think about kind of layering those various launches on top of each other, none huge in their own right, but you kind of stack them together. I mean, is there opportunity, as we think about ability to outgrow the market, you stack those together and maybe you do have a few points of growth as we look out kind of over the midterm?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. Yeah, for sure.

Matt Stanton
Equity Research Analyst, Jefferies

And like some of the bioprocess

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, for sure. I think on, like we said, ModTail definitely is getting traction, and ModTail kind of mimics what CleanCap did, like research use first, then a year later, it starts to move into the GMP, and then as trials progress, you get a broader adoption on CleanCap, and ModTail is going to follow a similar kind of arc or pathway. I think beyond that, as I explained, TriLink is now a very different company than it used to be.

It used to be known as a CleanCap company, but now with the breadth of products we have and the way customers approach us to build their mRNA constructs, we are giving them the whole suite of products. So to your point on those NPIs, and as we continue to innovate and offer design services and products that they want, it can definitely be a needle mover in terms of shifting growth that outpaces the market.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. And maybe on ModTail and maybe using CleanCap as some type of an analogy, right? You talked about launch last year went really well. I think you guys said you had $500 or so of revenue last year in only a few months, continue to add customers. I assume that is kind of run rating at a nice clip. I mean, is there a scenario where we are talking about ModTail, especially after GMP rollout, this is a tens of millions of dollar product, as we look out a few years, not unlike CleanCap, which followed that trajectory even before 2020 and kind of the COVID dynamics?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. My commercial guy and the modeler will definitely address that. Jimmy's deep into it.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

The short answer is I think we do see ModTail being even larger than CleanCap in a lot of ways. The way we sell it, we're already selling at a premium to CleanCap, and it's helping us not just sell more CleanCap, it's also helping us sell the full mRNA construct. Our customers are seeing incredible value because it's delivering higher protein expression, higher level of durability, and so it's leading to repeat purchases and customers' programs advancing. That's where it can get really exciting, where it can go from a purchase that's tens of thousands to hundreds of thousands, and then once it reaches the clinic, you're looking at customers that are going to buy four or five times that in terms of volume. We've seen the traction, and it's going to be significant and provide quite a bit of growth into next year.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. Then maybe just on the demand profile, right? You have CleanCap, this kind of play on the other side of the molecule. I imagine a lot's from existing customers that know CleanCap, know TriLink, but there's other enzymatic capping technologies or other capping technologies

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Matt Stanton
Equity Research Analyst, Jefferies

out there which could utilize this. Maybe just talk about demand profile to date, as well as kind of opportunity going forward as you educate

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Matt Stanton
Equity Research Analyst, Jefferies

those other kind of capping.

Raj Asarpota
CFO, Maravai LifeSciences

Definitely. ModTail is agnostic to capping, so enzymatic customers can also leverage ModTail. I think-

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

I would just say, when we analyze the 70 new or greater than 70 mRNA discovery customers, a big portion of that was coming from ModTail. So it's not only supporting existing customers, but we're adding new customers, which is new programs along the way that's driving the results. And it's pretty broad-based in terms of the customer.

Raj Asarpota
CFO, Maravai LifeSciences

I guess the point I was going to make, Jimmy, and maybe you should just address the attachment rate.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah. When we sell ModTail, greater than 90% of the time, we sell it along with CleanCap or other reagents as well.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. And maybe just remind us, you have GMP coming in 2027. It sounds like there is demand for that. Just talk about the rollout of GMP, how that kind of looks as we think about cadence of that rollout and customers starting to utilize it into

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah

Matt Stanton
Equity Research Analyst, Jefferies

2027. Sounds like more back half, but just kind of any finer point on the GMP rollout.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. The launch is on time, so that is going to happen over the next four weeks or so that are four to six weeks that are left in the year. Then as customers start to look at their qualification and how they are going to kind of progress, we think by the second half of 2027 is when you would start to see dollars in terms of being contributed from ModTail GMP.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. Maybe shifting gears to China. I think historically, TriLink's been relatively under-indexed there, especially relative to Cygnus. You are seemingly on the cusp of entering or potentially entering that market more meaningfully. You've made some moves on the IP front. I think you've hired or about to hire a head of commercial to kind of approach that. Maybe just talk about how the rollout or entrance of TriLink in China looks.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Matt Stanton
Equity Research Analyst, Jefferies

and maybe some of the kind of demand signals or conversations you're having with folks that give you kind of confidence that this is.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Matt Stanton
Equity Research Analyst, Jefferies

the right time and there's demand on the other side.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. Big picture, there's some over 800 companies doing mRNA and gRNA, right? And then about roughly 150 to 160 of those companies are in China. So it's a pretty meaningful number. As you think about China as a greenfield opportunity, because today we've got nothing in China for TriLink, but as these companies progress through their trials and they want to engage with global pharma or want to enter into the U.S. market, I think there's two things. One, those patents that we just talked about, those companies, if they have aspirations, they want to be on the right side of IP. So having those patents protects us in that regard.

Like you said, we've already onboarded a leader in China to develop distributor relationships and partnerships to make sure that once we get started, that we've got the right amount of feet on the street and the right partnerships. Then, I think beyond that, once you start to have those feet on the street and once you start to make some inroads, I think the opportunity is huge. It just won't happen a lot next year, but beyond that, we should see a pretty big opportunity.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. That's helpful. Maybe going back to the mid to long-term targets you laid out on one of the first slides earlier. I think the growth side is pretty clear. Just on the margin side, you didn't put out formal margin targets, but you guys have done a really good job on the cost side, right? We're back to this kind of 70% incremental margin story. Just how do we think about the margin trajectory within that kind of midterm framework, especially given the very healthy margins at Cygnus, TriLink continues to improve. Is there a pathway to mid-20s or better type EBITDA margins within the construct you have of the top line given where incremental shakeout for this business?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. I would say actually that that is conservative.

Matt Stanton
Equity Research Analyst, Jefferies

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Because again, if you just look at our model that's been reset and what we're saying is 70% of every incremental revenue dollar or 70% falls to the bottom line. So as you think about the growth that we're seeing within Discovery and GMP, and Cygnus is steady, but if that also in terms of the mix is there, you're going to see those margins get significantly higher. Again, for 2027, we're not giving guidance because we just. But long term, that's how you would need to think about it, is in terms of the model, what that growth looks like. And like we've said before, we can flow hundreds of millions of dollars of revenue through the P&L without increasing our operating expenses or CapEx.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. And maybe just in that vein, gross margins, I think you guys have taken up the guidance there twice this year over-

I think 1,600 basis points of expansion this year, so very meaningful-

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Matt Stanton
Equity Research Analyst, Jefferies

progress. As we think about that longer term construct, is there scope and visibility to push gross margins above 60% as we think about the opportunity there?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. I'll give that to Jimmy because he's got initiatives that he's driving to make that even better.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah. I mean, we're doing a lot to improve margins and really the number one driver of that improvement is going to be the drop through that Raj mentioned. Every dollar at a minimum is going to drop through 70% to EBITDA, and it's probably equivalent to that or higher at gross margin. But beyond that, we continue to find initiatives. AI is a big one for us. We've rolled that out across the company and have gotten significant adoption. We've collected hundreds of use cases now, and we think that'll just overall help improve manufacturing efficiency and continue to drive some margin. I think being north of 60% in the near term is very doable.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. And maybe just on that AI deployment, hundreds of use cases sounds encouraging. Are there one or two or three that are really sticking out in terms of optimizing production today or in the near term versus what might be more longer term? How do you kind of-

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah. I think the biggest thing, if you think about TriLink, we have decades of mRNA experience and data that's sitting around. For the team, they've spent a lot of time collecting that data and figuring out how to feed it into models, both off-the-shelf models, but also we have proprietary internal models that were purchased a year and a half ago through our Officinae Bio acquisition. We're in a position to really drive value in AI, not just because of the technology that's currently out there to everyone, but also the data that we have that nobody else has.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. That sounds like it's a potential revenue opportunity if you're packaging or selling that data?

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Exactly. Right now, to an extent, we are already offering some of that service through our mRNAbuilder.

Matt Stanton
Equity Research Analyst, Jefferies

Yeah.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

That is already getting significant adoption, but we can further roll out more and more capabilities because of the dataset we have.

Raj Asarpota
CFO, Maravai LifeSciences

Matt, even on the commercial side, if you think about the tools that we have available now through AI, like Jimmy said, the data is so extensive that account planning is so accurate, so precise. The insights we have into each of our customers is as good outside the company as those individuals inside the company would have. It just gives us a lot of leverage versus cold calling a customer. You have really good account planning tools.

Matt Stanton
Equity Research Analyst, Jefferies

Okay. With that, we are out of time. Appreciate it both. Thank you.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Thank you.